Lumbosacral Radicular Pain - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights:

• Lumbar radiculopathy is a self-limited injury to the nerve roots of the lumbar spine. It can present as excruciating, burning, or stinging pain, radiating down the leg, decreased sensation of the legs, numbness and tingling, and in more severe cases, muscle weakness.
• According to DelveInsight's estimates, lumbosacral radicular pain also known as lumbosacral radiculopathy, is very common. On average, 3 to 5% of adults will experience symptoms in their lifetime and L5 radiculopathy is the single most common Lumbar Radiculopathy.
• In 2023, the United States accounted for approximately 50% of the total cases of lumbosacral radiculopathy in the 7MM.
• Lumbosacral radicular pain pipeline is also not so robust but possesses a potential drug candidate i.e. SEMDEXA, which is currently in Phase III clinical trials developed by Scilex Holdings.

DelveInsight's "Lumbosacral Radicular Pain- Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Lumbosacral Radicular Pain, historical and forecasted epidemiology as well as the Lumbosacral Radicular Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Lumbosacral Radicular Pain market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Lumbosacral Radicular Pain market size from 2020 to 2034. The report also covers current Lumbosacral Radicular Pain treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Lumbosacral Radicular Pain Understanding and Treatment Algorithm

Lumbosacral Radicular Pain Overview, Country-Specific Treatment Guidelines and Diagnosis

Acute lumbosacral radiculopathy is a diffuse disease process that affects more than one underlying nerve root, causing pain, loss of sensation, and motor function depending on the severity of nerve compression. Lumbosacral radiculopathy is very common. Most cases of lumbosacral radiculopathy are self-limited. The most common symptom in radiculopathy is paresthesia.

The most common causes of lumbar radiculopathy are either a herniated disc with resultant nerve root compression or spondylosis.

To diagnose a herniated disc as a source of a patient's pain, it is important to review the complete history and physical and making sure that the symptoms match the imaging results. Patients with lumbar radicular pain often respond to conservative management.

The Lumbosacral Radicular Pain report provides an overview of Lumbosacral Radicular Pain pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient's journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Lumbosacral Radicular Pain Treatment

Treatment varies depending on the etiology and severity of symptoms. Conservative management of symptoms is generally considered the first-line treatment. Medications are used to manage pain symptoms, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, anti-epileptic medications that can be used to treat nerve-related pain (e.g., gabapentin), and in severe cases, low-dose opiates. Systemic steroids are an option for lumbosacral radiculopathy, which can result in modest benefits.

Non-pharmacological interventions are often utilized as well. Physical therapy, acupuncture, chiropractic manipulation, and traction are all commonly used to treat lumbosacral radiculopathy.

Lumbosacral Radicular Pain Epidemiology

The Lumbosacral Radicular Pain epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Lumbosacral Radicular Pain epidemiology is segmented with detailed insights into Total Diagnosed Prevalent Cases, Severity-based Diagnosed Prevalent Cases of Lumbosacral Radicular Pain, and Prevalent cases of Lumbosacral Radicular Pain by species for the years [2020-2034].

• Lumbosacral radiculopathy affects approximately 3% to 5% of the population. It is equally distributed between men and women.
• The primary risk factor for lumbosacral radiculopathy is age, as it often occurs due to degenerative changes in the spinal column.
• Patients with lumbosacral radiculopathy commonly experience pain, numbness, and weakness in the back, groin, or leg. The most frequent causes are compressive intervertebral disc herniation and degenerative spondylosis.

Lumbosacral Radicular Pain Drug Chapters

The drug chapter segment of the Lumbosacral Radicular Pain report encloses a detailed analysis of Lumbosacral Radicular Pain late-stage (Phase III) pipeline drugs. It also deep dives into the Lumbosacral Radicular Pain pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Emerging Drugs

SEMDEXA: Scilex Holding

SEMDEXA is a novel injectable corticosteroid gel formulation product in development for the treatment of lumbosacral radicular pain, which contains no preservatives, surfactants, solvents, or particulates. The CLEAR Trial (Corticosteroid Lumbosacral Epidural Analgesia for Radiculopathy) was designed to investigate safety and analgesic effects of a single and repeat transforaminal injections of SEMDEXA compared to placebo (saline injection). The trial enrolled 401 low back pain subjects with unilateral intervertebral lumbar disc herniation, resulting in radicular pain symptoms of moderate to severe leg pain. It is the largest known randomized well-controlled trial in sciatica using epidural steroid injections.

In June 2024, Scilex Holding announced a publication in PAIN journal regarding Phase III of pivotal registration trial of SEMDEXA in lumbosacral radicular pain.

Lumbosacral Radicular Pain Market Outlook

Key player, Scilex Holdings is evaluating its lead candidate SEMDEXA in late stage of clinical development, respectively. They aim to investigate their products for the treatment of lumbosacral radicular pain.

The market size of lumbosacral radicular pain in the seven major markets is expected to increase substantially from 2024 with upcoming drugs.

• Physicial therapy and surgery plays a major role in the treatment of lumbosacral radiculopathy, with conservative pain management approach being used only in certain cases, as most patients end up being treated for the underlying disease itself. Hence only in those patients specifically requiring pharmacological pain management, drugs like NSAIDs, anticonvulsants, and antidepressants are used.
• Although established guidelines discourage the usage of opioids, reserving their usage only to patients with severe pain, they have still been observed to be used frequently in the clinical setting.

Lumbosacral Radicular Pain Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Lumbosacral Radicular Pain Activities

The report provides insights into different therapeutic candidate in Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Lumbosacral Radicular Pain emerging therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Nationwide Children's Hospital, Columbus, OH, the United States, University Hospitals Dorset NHS Foundation Trust, North Shore University Health System, Evanston, Illinois, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of Lumbosacral Radicular Pain. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of lumbosacral radicular pain, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the lumbosacral radicular pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM lumbosacral radicular pain market.

Lumbosacral Radicular Pain Report Insights

• Patient Cases
• Therapeutic Approaches
• Lumbosacral Radicular Pain Pipeline Analysis
• Lumbosacral Radicular Pain Market Size and Trends
• Existing and future Market Opportunity

Lumbosacral Radicular Pain Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Lumbosacral Radicular Pain Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL's feedback on emerging therapies
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Lumbosacral Radicular Pain Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What is the growth rate of the 7MM Lumbosacral Radicular Pain treatment market?
• What was the Lumbosacral Radicular Pain total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Lumbosacral Radicular Pain?
• How many companies are developing therapies for the treatment of Lumbosacral Radicular Pain?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Lumbosacral Radicular Pain Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.